2018 Advisory Board
Jonathan Waldstreicher, MD, MBA
Jonathan Waldstreicher, Principal, joined Apple Tree Partners in 2013 to invest in medical devices. After incubating an interventional pulmonary technology for two years, Jon founded Gala Therapeutics in Silicon Valley and assumed the CEO role to further its development. Prior to joining ATP, Jon was a Director, Global Surgery R&D, at Johnson & Johnson where…
Read MoreMichelle Turenne
After 17 years in the pharmaceutical and biotech industries working in both field sales and brand and portfolio marketing, Michelle joined the staff of the American Thoracic Society in 2007, serving as a liaison between the Society and its industry partners. Her experience launching multi-million dollar products through a comprehensive corporate association strategy as well…
Read MoreTara Butler, MD
Tara Butler came to Ascension Ventures in 2002 after completing a residency in obstetrics and gynecology at Washington University in St. Louis. She primarily focuses on investments in the medical device and diagnostics sector. Tara has been a board member or observer at several Ascension Ventures portfolio companies, including Apama Medical, Augmenix, CHF Solutions, Confluent…
Read MoreIrina Petrache, MD
Irina Petrache is Professor of Medicine at National Jewish Health and University of Colorado, Denver, CO. Dr. Petrache received her medical degree from the “Carol Davila” University of Medicine and Pharmacy in Bucharest, Romania and received postgraduate training in Internal Medicine at Saint Luke’s/St Vincent Medical Center/Case Western Reserve University in Cleveland, OH; and in…
Read MoreJames Donohue, MD
Dr. Donohue’s research interests include new therapeutics in chronic obstructive pulmonary disease, alpha-1 antitrypsin deficiencies and asthma. He has previously served on the editorial advisory boards of numerous journals including COPD: Journal of Chronic Obstructive Pulmonary Disease, Medscape Pulmonary Medicine and Current Respiratory Medical Review, and is an ad hoc reviewer for many journals, including…
Read MoreColin Reisner, MD
Dr. Colin Reisner is Senior Vice President and Head of Late Stage RIA (Respiratory, Inflammation & Autoimmunity), BioPharmaceuticals R&D, AstraZeneca. He is an innovative leader with more than 20 years of international experience at top-tier companies, having previously workred at Boehringer Ingelheim, GSK and Novartis. Colin has extensive experience in both large and small companies,…
Read MoreBernard Coulie, MD, PhD
Pliant CEO Bernard Coulie, MD, PhD brings to the company more than 15 years of senior leadership experience and drug development expertise. He joined Pliant from ActoGeniX (acquired by Intrexon Corporation in February 2015), where he was CEO, Chief Medical Officer and Co-Founder. In these positions, Dr. Coulie played an integral role in advancing the…
Read MoreGregory Grunberg, MD
Dr. Grunberg is a Managing Director of Longitude Capital. Prior to joining Longitude Capital in 2012, Dr. Grunberg was a Principal at Rho Ventures and an Engagement Manager at McKinsey & Company. Dr. Grunberg is a board-certified physician in Internal Medicine and completed his residency at Cornell’s New York Presbyterian Hospital. He has maintained a…
Read MoreTheodore Reiss, MD, MBE, ATSF
Ted began his career with Merck & Co. in Clinical Pharmacology and Pulmonary-Immunology and eventually was responsible for other therapeutic areas within the company including Gastroenterology. Ted also worked at Covance, fostering an integrated approach to drug development, Vanderbilt School of Medicine in Molecular Toxicology and the Clinical and Translational Science Institute (CTSI) and joins…
Read MoreMahendra Shah, PhD
Mahendra Shah, is a highly successful pharmaceutical entrepreneur and executive who has been with Vivo Capital, LLC since March 2010. He currently serving as managing director. Dr. Shah is the founder and executive chairman of Semnur Pharmaceuticals. He previously served as chairman of the board of Essentialis, and currently serves as a board member of…
Read More